• 5 min read
• Published on 25 July 2025
Listen to article
6:05Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article
Let’s be honest, the market has the attention span of a caffeinated gnat. It flits from one shiny object to the next, chasing meme stocks, quarterly earnings beats, and whatever a charismatic billionaire tweets about at 3 AM. It’s exhausting. But while everyone is gawping at the penthouse suites of the tech world, I find myself more interested in the plumbing. The real, foundational, and frankly, rather unglamorous infrastructure that holds the entire glittering skyscraper up.
I’m talking about platform companies. This isn’t a new concept, but it’s one that often gets lost in the noise. A platform isn’t just a product, it’s an entire ecosystem. Think of Microsoft Windows in the nineties. It wasn’t just an operating system, it was the very ground upon which a thousand other software companies built their fortunes. Or look at Amazon’s cloud services today, the digital landlord for a huge chunk of the internet.
These companies build the roads, lay the pipes, and supply the power. Once an industry becomes dependent on their infrastructure, it’s incredibly difficult to switch. Take Intuitive Surgical. They don’t just sell a fancy robot for operations. They sell a whole system, complete with training, instruments, and support. A hospital that invests in their da Vinci system isn’t just buying a machine, it’s buying into a long term relationship. The cost and hassle of leaving become almost unthinkable. That, to me, is a powerful position to be in.
This theme of indispensable infrastructure runs deep. You have companies like Illumina, which has become the default provider of DNA sequencing technology. Nearly every major breakthrough in genetic research, from medicine to agriculture, likely relies on their machines. They are, in essence, building the library of life itself.
Then you have my personal favourite, the Dutch firm ASML. This company has a complete monopoly on the ridiculously complex machines needed to make the world’s most advanced computer chips. Each machine costs a fortune, contains more parts than a space shuttle, and takes an age to build. Without ASML, there would be no cutting edge iPhones, no superpowered NVIDIA graphics cards, nothing. They are the ultimate gatekeepers. It’s a collection of companies that, to my mind, fit this mould, a sort of who's who of the quiet giants. You can see the full list in the Patient Platforms basket.
Now, here’s the catch. Investing in the plumbers of the world requires a virtue that is in desperately short supply today, patience. These are not get rich quick schemes. Building foundational technology takes years, sometimes decades, to pay off. You have to endure regulatory hurdles, market scepticism, and the gut wrenching volatility that comes with any long term vision.
There are, of course, significant risks. A new technology could appear and render a dominant platform obsolete overnight. Competition is always lurking, and these companies often trade at valuations that might make your eyes water, especially when profits seem so far off in the future. This is not a strategy for the faint of heart. It’s a bet that the deep, structural advantages these companies are building will eventually create immense value. It’s a belief that in a world obsessed with the next big thing, the companies building the stage for it might just be the most interesting players of all.
View the full Basket:Patient Platforms
View the full Basket:Patient Platforms
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article